Private Trust Co. NA boosted its holdings in Alexion Pharmaceuticals (NASDAQ:ALXN) by 28.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,640 shares of the biopharmaceutical company’s stock after buying an additional 2,377 shares during the period. Private Trust Co. NA’s holdings in Alexion Pharmaceuticals were worth $1,320,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in ALXN. Delpha Capital Management LLC acquired a new position in Alexion Pharmaceuticals in the fourth quarter valued at approximately $102,000. Point72 Asia Hong Kong Ltd lifted its holdings in Alexion Pharmaceuticals by 3,156.7% in the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 947 shares during the period. CNB Bank acquired a new position in Alexion Pharmaceuticals in the fourth quarter valued at approximately $150,000. Lucia Wealth Services LLC acquired a new position in Alexion Pharmaceuticals in the first quarter valued at approximately $191,000. Finally, Financial Gravity Wealth Inc. acquired a new position in Alexion Pharmaceuticals in the first quarter valued at approximately $211,000. Institutional investors and hedge funds own 92.22% of the company’s stock.
ALXN has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $127.00 target price on the stock in a report on Thursday, April 19th. Stifel Nicolaus increased their target price on shares of Alexion Pharmaceuticals from $151.00 to $155.00 and gave the stock a “buy” rating in a report on Friday, April 27th. Credit Suisse Group reiterated an “outperform” rating and issued a $149.00 target price (up from $147.00) on shares of Alexion Pharmaceuticals in a report on Friday, March 16th. Nomura increased their target price on shares of Alexion Pharmaceuticals to $165.00 and gave the stock a “buy” rating in a report on Thursday, April 12th. Finally, BidaskClub lowered shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $160.00.
In related news, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The shares were acquired at an average cost of $120.79 per share, for a total transaction of $1,207,900.00. Following the completion of the acquisition, the director now directly owns 26,333 shares in the company, valued at approximately $3,180,763.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John J. Orloff sold 2,115 shares of the firm’s stock in a transaction on Friday, June 8th. The stock was sold at an average price of $118.53, for a total transaction of $250,690.95. Following the sale, the executive vice president now owns 31,790 shares in the company, valued at $3,768,068.70. The disclosure for this sale can be found here. Company insiders own 4.35% of the company’s stock.
Shares of NASDAQ:ALXN opened at $125.00 on Tuesday. Alexion Pharmaceuticals has a 12 month low of $102.10 and a 12 month high of $149.34. The company has a current ratio of 3.35, a quick ratio of 2.86 and a debt-to-equity ratio of 0.33. The firm has a market cap of $27.62 billion, a P/E ratio of 24.22, a P/E/G ratio of 1.12 and a beta of 1.08.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.18. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business had revenue of $930.90 million for the quarter, compared to analyst estimates of $920.50 million. During the same period last year, the business posted $1.38 earnings per share. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. research analysts predict that Alexion Pharmaceuticals will post 6.28 earnings per share for the current fiscal year.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.